Exaprin Pain Reliever Tablets Recalled for cGMP Deviations
Ultra Seal Corporation is recalling Exaprin pain reliever tablets nationwide due to cGMP (current good manufacturing practices) deviations. The recall affects approximately 1.14 million packets distributed across the United States.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II voluntary recall based on cGMP deviations without any reported illnesses, injuries, or hospitalization. Per the rubric, this falls into the Moderate category as a voluntary precautionary recall with manufacturing deficiency concerns that have not resulted in reported harm.
Plain-English summary
Ultra Seal Corporation, manufacturing for HARTHealth of Seattle, Washington, is recalling Exaprin pain reliever tablets in 2-tablet packets (containing acetaminophen 110 mg, aspirin 162 mg, caffeine 32.4 mg, and salicylamide 152 mg) nationwide within the United States. The recall was initiated on January 24, 2022, and involves approximately 1,140,1641 packets with Lot # AK9796 and expiration date 09/2022.
The reason for this recall is cGMP (current good manufacturing practices) deviations, as classified by the FDA as Class II. This is a voluntary recall initiated by the firm, with the FDA making its center classification determination on January 31, 2022. The recall was terminated on October 16, 2023.
No specific instructions for consumer action are provided in the recall notice beyond the termination date. Consumers with questions about this product should contact the manufacturer or the FDA's drug safety reporting channels.
The recalled product
- Product
- Exaprin pain reliever (acetaminophen 110 mg, aspirin 162 mg, caffeine 32.4mg, salicylamide 152mg) tablets, 2- tablet packets, Manufactured for: HARTHealth Seattle, WA 98124
- Manufacturer
- Ultra Seal Corporation
- Hazard
- cgmp-deviation
- manufacturing-deficiency
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: AK9796
- Exp. Date 09/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27